Citi slashes Human Genome target on slow Benlysta sales

Doctors aren't flocking to Benlysta, the new lupus treatment developed by Human Genome Sciences ($HGSI) and marketed in partnership with GlaxoSmithKline ($GSK), Citi analyst Dr. Yaron Werber says in a new note to investors. As the Associated Press reports, Werber cut his price target on HGS stock to $15 from $26 on the slow uptake. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.